238 related articles for article (PubMed ID: 10547218)
1. Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter.
Reyes AJ; Taylor SH
Cardiovasc Drugs Ther; 1999 Sep; 13(5):371-98. PubMed ID: 10547218
[TBL] [Abstract][Full Text] [Related]
2. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.
Reyes AJ; Leary WP
Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():29-44. PubMed ID: 8435375
[TBL] [Abstract][Full Text] [Related]
3. Clinicopharmacological reappraisal of the potency of diuretics.
Reyes AJ; Leary WP
Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():23-8. PubMed ID: 8435374
[TBL] [Abstract][Full Text] [Related]
4. Renal excretory profiles of loop diuretics: consequences for therapeutic application.
Reyes AJ
J Cardiovasc Pharmacol; 1993; 22 Suppl 3():S11-23. PubMed ID: 7506333
[TBL] [Abstract][Full Text] [Related]
5. Effects of diuretics on renal excretory function.
Reyes AJ
Eur Heart J; 1992 Dec; 13 Suppl G():15-21. PubMed ID: 1486900
[TBL] [Abstract][Full Text] [Related]
6. Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects.
Reyes AJ
Drugs; 1991; 41 Suppl 3():35-59. PubMed ID: 1712714
[TBL] [Abstract][Full Text] [Related]
7. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
8. An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats.
Schnackenberg CG; Merz E; Brooks DP
Br J Pharmacol; 2003 Aug; 139(8):1383-8. PubMed ID: 12922924
[TBL] [Abstract][Full Text] [Related]
9. Failure of indomethacin to impair the diuretic and natriuretic effects of the loop diuretic torasemide in healthy volunteers.
van Ganse E; Douchamps J; Deger F; Staroukine M; Verniory A; Herchuelz A
Eur J Clin Pharmacol; 1986; 31 Suppl():43-7. PubMed ID: 3536531
[TBL] [Abstract][Full Text] [Related]
10. Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.
Knauf H; Mutschler E
Eur J Clin Pharmacol; 1990; 39(4):337-43. PubMed ID: 2076714
[TBL] [Abstract][Full Text] [Related]
11. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure.
Kissling KT; Pickworth KK
Pharmacotherapy; 2014 Aug; 34(8):882-7. PubMed ID: 24990816
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new loop diuretic (muzolimine) in cirrhosis with ascites: comparison with furosemide.
Bernardi M; De Palma R; Trevisani F; Santini C; Patrono D; Motta R; Servadei D; Gasbarrini G
Hepatology; 1986; 6(3):400-5. PubMed ID: 3519416
[TBL] [Abstract][Full Text] [Related]
14. Torasemide. An update of its pharmacological properties and therapeutic efficacy.
Dunn CJ; Fitton A; Brogden RN
Drugs; 1995 Jan; 49(1):121-42. PubMed ID: 7705212
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
16. Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis.
Knauf H; Mutschler E; Velazquez H; Giebisch G
Eur J Clin Pharmacol; 2009 May; 65(5):465-72. PubMed ID: 19229529
[TBL] [Abstract][Full Text] [Related]
17. The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects.
Knauf H; Bailey MA; Hasenfuss G; Mutschler E
Eur J Clin Pharmacol; 2006 Nov; 62(11):885-92. PubMed ID: 16964522
[TBL] [Abstract][Full Text] [Related]
18. Torasemide. A review of its pharmacological properties and therapeutic potential.
Friedel HA; Buckley MM
Drugs; 1991 Jan; 41(1):81-103. PubMed ID: 1706990
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Design of the "Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) Trial:" A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Combined Diuretic Therapy (Loop Diuretics With Thiazide-Type Diuretics) Among Patients With Decompensated Heart Failure.
Trullàs JC; Morales-Rull JL; Casado J; Freitas Ramírez A; Manzano L; Formiga F;
J Card Fail; 2016 Jul; 22(7):529-36. PubMed ID: 26576715
[TBL] [Abstract][Full Text] [Related]
20. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
